Vertex Pharmaceuticals Inc
F:VX1

Watchlist Manager
Vertex Pharmaceuticals Inc Logo
Vertex Pharmaceuticals Inc
F:VX1
Watchlist
Price: 392.3 EUR 1.06%
Market Cap: 101.3B EUR

Wall Street
Price Targets

VX1 Price Targets Summary
Vertex Pharmaceuticals Inc

Wall Street analysts forecast VX1 stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for VX1 is 430.69 EUR with a low forecast of 286.5 EUR and a high forecast of 545.16 EUR.

Lowest
Price Target
286.5 EUR
27% Downside
Average
Price Target
430.69 EUR
10% Upside
Highest
Price Target
545.16 EUR
39% Upside
Vertex Pharmaceuticals Inc Competitors:
Price Targets
EDIT
Editas Medicine Inc
128% Upside
688382
InventisBio Co Ltd
68% Upside
688363
Bloomage Biotechnology Corp Ltd
9% Upside
9926
Akeso Inc
54% Upside
ELDN
Eledon Pharmaceuticals Inc
420% Upside
RNA
Avidity Biosciences Inc
3% Upside
6990
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
29% Upside
300653
Yantai Zhenghai Bio-Tech Co Ltd
26% Upside

Revenue
Forecast

Revenue Estimate
Vertex Pharmaceuticals Inc

For the last 13 years the compound annual growth rate for Vertex Pharmaceuticals Inc's revenue is 17%. The projected CAGR for the next 4 years is 10%.

17%
Past Growth
10%
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Vertex Pharmaceuticals Inc

For the last 13 years the compound annual growth rate for Vertex Pharmaceuticals Inc's operating income is 26%. The projected CAGR for the next 4 years is 15%.

26%
Past Growth
15%
Estimated Growth
Estimates Accuracy
-21%
Average Miss

Net Income
Forecast

Net Income Estimate
Vertex Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-5%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is VX1's stock price target?
Price Target
430.69 EUR

According to Wall Street analysts, the average 1-year price target for VX1 is 430.69 EUR with a low forecast of 286.5 EUR and a high forecast of 545.16 EUR.

What is Vertex Pharmaceuticals Inc's Revenue forecast?
Projected CAGR
10%

For the last 13 years the compound annual growth rate for Vertex Pharmaceuticals Inc's revenue is 17%. The projected CAGR for the next 4 years is 10%.

What is Vertex Pharmaceuticals Inc's Operating Income forecast?
Projected CAGR
15%

For the last 13 years the compound annual growth rate for Vertex Pharmaceuticals Inc's operating income is 26%. The projected CAGR for the next 4 years is 15%.

Back to Top